HALOZYME THERAPEUTICS, INC.

Licenses a drug delivery platform to biopharma, converting IV drugs to subcutaneous injections.

HALO | NDAQ

Overview

Corporate Details

ISIN(s):: US40637H1095
LEI:
Country:: United States of America
Address:: 12390 EL CAMINO REAL, 92130 SAN DIEGO
Website:: https://www.halozyme.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Halozyme Therapeutics, Inc. is a biotechnology company focused on its proprietary drug delivery technology platform, ENHANZE®. This technology facilitates the subcutaneous (under-the-skin) delivery of injectable drugs and biologics that are often administered intravenously. Halozyme licenses its ENHANZE® technology to global biopharmaceutical companies, enabling them to develop new formulations of their therapies. This model aims to reinvent the patient experience by reducing treatment burden and shortening administration times, particularly in therapeutic areas such as oncology. The company's commercial portfolio is primarily built on royalties and milestone payments derived from its partners' sales of products utilizing the ENHANZE® platform.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all HALOZYME THERAPEUTICS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HALOZYME THERAPEUTICS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for HALOZYME THERAPEUTICS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Larimar Therapeutics, Inc. Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.	United States of America	LRMR
LEAP THERAPEUTICS, INC. Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.	United States of America	LPTX
Lidds AB Develops oncology drugs using a technology for local, controlled, and sustained drug release.	Sweden	LIDDS
LigaChem Biosciences Inc. Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.	South Korea	141080
LIGAND PHARMACEUTICALS INC Acquires drug royalties and licenses proprietary technologies to biopharmaceutical partners.	United States of America	LGND
LIKE,Inc. Provides comprehensive lifestyle support in childcare, human resources, and nursing care services.	Japan	2462
Linical Co., Ltd. Global CRO providing full-service drug development support for biopharma companies.	Japan	2183
Linkers Corporation A technology matchmaking platform for manufacturers to solve challenges and foster innovation.	Japan	5131
Lipidor AB Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.	Sweden	LIPI
MAIA Biotechnology, Inc. Developing telomere-targeting immuno-oncology therapies for difficult-to-treat cancers.	United States of America	MAIA